TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Thrombin generation tests improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thromboelastography improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total serum cholesterol reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reynolds cardiovascular risk score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with one or more adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious lamotrigine-attributed adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients leading to premature withdrawal due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3 to 5 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility and validity of MOS-HIV
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum MCP‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: contrast-induced nephropathy
Endpoint domain: Adverse events/effects
Primary endpoint: ischaemic stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Upper extremity motor control (Fugl‐Meyer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active reaching range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self‐reported quality and amount of arm use (Motor Activity Log)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Subcutaneous Adipose Tissue (SAT) area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visceral Adipose Tissue (VAT) area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAT/SAT ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of days to parasite clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitological treatment failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS of knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee joint stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoporosis knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Calcium intake from food (% of RDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of osteoporosis medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: non-fatal events (reinfarction, need for additional revascularization, re-hospitalization for ischemic event)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of restenosis at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of target lesion revascularization (TLR) at 6 and 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of amputation at 6 and 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: Percent-predicted VO2 max improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in total MADRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continence success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically fully recovered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significantly effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pterygium recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: duration of procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of side‐effects
Endpoint domain: Adverse events/effects
Primary endpoint: Time to diverge from full health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average decline in EQ‐5D index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average decline in EQ‐5D VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intramuscular PCr content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Internal root resorption
Endpoint domain: Adverse events/effects
Primary endpoint: Neurologic success (improvement or maintenance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for secondary surgeries
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Medication usage (not on strong narcotics or muscle relaxants)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Half emptying times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dyspepsia score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy in T staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity in evaluating N0 class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of oesophageal invasion determination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enhancement of EF skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal learning and delayed memory enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of physiological abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of Rapid Response Team (RRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Q-Tc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum P-R interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neurological sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blinded scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Editors' decisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct identification of authors by blinded reviewers
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Tendon thickness decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to achieve FeO2 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in protein C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: markers of thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Probability of pathological oesophageal reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in signs and symptoms of arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of endoscopically determined gastroduodenal ulcers
Endpoint domain: Adverse events/effects
Primary endpoint: BTV (Bronchial Temperature Variation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnostic accuracy of erosion detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of imaging techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-mastectomy pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rescue analgesia consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adverse events post-discharge
Endpoint domain: Adverse events/effects
Primary endpoint: Medication appropriateness index (MAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach plasma glucose below 115 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycemia after 2 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycemia after 4 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ability to apply and retain knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: glycosylated hemoglobin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fasting serum glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: student self-confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: smoking-knowledge test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Not at risk of an AEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: all-cause mortality plus cardiovascular hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: quantitative motion data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acquisition time reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rocuronium effective dose(95) (ED(95))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until 25% of first response of train‐of‐four (TOF) recovery (Dur(25))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until 0.8 TOF ratio recovery (Dur(0.8))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure measurement frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in scheduled visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Step length asymmetry ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip maximal extension moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal dorsiflexion angle for the ankle in the swing phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abolition of GSV reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in TCD velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GCS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall neurological outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: All-cause re-hospitalizations at 30 days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rebleeding within 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in lung function (IC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in functional residual capacity (FRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: subjects global assessment of overall treatment efficacy (OTE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvement in liver histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in laboratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prospective alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abdominal symptom perception score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average pain over the last 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced intake of energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improved Healthy Eating Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Protective seropositivity for measles, rubella, and mumps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroresponse (2-fold rise from baseline antibody titers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-treatment declines in prostate-specific antigen of > or = 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to prostate-specific antigen progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Power reductions in the LF band of the HRV frequency spectrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of REM sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Reduction in risk behavior scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Problem actuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytology results (no dysplasia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regression of cervical lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of myoclonus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Quality of Life (QLS scores)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: BPRS total % change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairments in clustering and switching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bowel opening frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ulcer healing score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-reactive protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: highest anesthetized cephalic dermatome level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: request for supplemental bupivacaine for inadequate analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: bacterial growth at culture sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: recolonization at culture sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clotting time (CT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Microvascular bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Increased odds for IFG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inversely associated with IGT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in total inflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Increase in PME ratios in response to amphetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of nangibotide
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic properties (clearance and half-life)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral blood HBV-specific CTL surface PD-1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HBV-specific CTL level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HBV DNA level becoming negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Nalbuphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first analgesic rescue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC transfusion reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Need for massive transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intubation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: plasma ß‐carotene concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Explicit bias on the Anti-Fat Attitudes Test (AFAT)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decrease in symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: six-month in-stent late lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-stent net volume obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conformance of care with recommended practices
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prescription rate of lipid modifying therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: alleviation of continuous and lancinating pain and allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in IL-8 in the CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NDI scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of second surgeries at adjacent levels
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Systemic absorption of estriol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal maturation value improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Index of Erectile Function-ED domain score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erection Hardness Score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PM2.5 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Air quality outcomes
Primary endpoint: Decrease in inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of positive psychopathology scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of activation factor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 2 nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality from pancreatic carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Rate of incidence of pancreatic carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: operator radiation exposure (RE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nurse radiation exposure (RE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Second handover scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early resumption of sex after circumcision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in the treatment of erectile dysfunction (ERD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-PRP geometric mean titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of fat/adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiometabolic risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in sleep complaints
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Good outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity of pneumonia and SIRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CMAP decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of paralytic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of systolic and diastolic blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RDQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: GERD symptom scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes